These inhibitors can help reduce AML progression and improve patient outcomes [6].Examples of FLT3 inhibitors include midostaurin, gilteritinib, sorafenib, quizartinib, crenolanib, ponatinib, and FF-10101, which havebeen approved for the treatment of AML with FLT3 mutations. Here, FLT3 is linked to acute myeloid leukemia.